Inclusion Criteria:

- Previously untreated, histological documented stage IIIB (not amenable for radical
regional therapy) or stage IV squamous cell carcinoma of lung. At least one
measurable lesion as defined by RECIST criteria.

- At least 18 years of age.

- ECOG PS 0~1

- Patients have no previously malignant tumor history except cured cervical carcinoma
in situ, basal cell carcinoma or superficial bladder cancer. Patients are also
eligible if they have received a chemotherapy regimen as neoadjuvant or adjuvant
chemotherapy and the disease recurred over 12 months since the finishing of
neoadjuvant or adjuvant chemotherapy.

- neutrophil ≥ 1.5 x 109 /L, Hemoglobin > 90 g/L, Platelet count > 100x109/L.

- Total bilirubin ≤ 1.5 x upper limit of normal. ALT and AST < 2.5 x upper limit of
normal without liver metastasis, ALT and AST < 5 x upper limit of normal with liver
metastasis. Serum creatinine < 1.5 x upper limit of normal.

- Urine pregnancy test is negative for woman.

- Estimated life expectancy is at least 3 months.

- Patient comply with the clinical trial protocal.

- Informed consent must be signed.

Exclusion Criteria:

- Patients who are currently undergoing other anti-tumor therapy.

- Patients who was enrolled in any other clinical trial within 4 weeks of study entry.

- Any physical examination finding, or clinical laboratory finding giving reasonable
suspicion of a disease or condition that contraindicates the use of any study
medication or render the subject at high risk from treatment.

- Central nervous system (CNS) tumor or metastatic tumor.

- Serious mental disorder.

- Serious dysgnosia.

- Other serious comorbidity.

- Alcohol or drug dependence.

- Previously allergic to drugs used in the study.